

Clinical characterization,
genetic screening
and genotype-phenotype associations in

CEREBELLAR AND BRAINSTEM CONGENITAL DEFECTS (CBCDs)

Sara Nuovo, MD


Università degli Studi di Salerno
IRCCS Fondazione Santa Lucia, Roma
saranuovo84@gmail.com



Coordinatore: Prof. P. Monteleone

Tutor: Prof. P. Vajro

18 Giugno 2020




OUR RECRUITED COHORT (FROM 2003)

- ~ **600** Joubert Syndrome (JS)
- ~ **670** other Cerebellar and Brainstem Congenital Defects (CBCDs)
- Clinical questionnaire, brain MRI, biological samples

In a subset of patients:


- neuropsychological assessment (++JS)
- DTI-tractography
- ≥18 months follow-up (up to 50%)
- genetic studies




MRI




Joubert Syndrome




Tubulinopathy




Pontocerebellar hypoplasia



Non-progressive congenital ataxia




JOUBERT SYNDROME



MOLECULAR DIAGNOSIS

- prognostic value
- prenatal diagnosis



DIAGNOSIS based on
NEUROIMAGING

>40 known GENES

proteins of the
primary cilium or its
apparatus

(Shh, Wnt, PDGF α)

JBTS	locus	Gene	Prevalent JS phenotypes
JBTS1	9q34	INPP5E	JS±retina; (JS+fegato)
JBTS2	11q12	TMEM216	JS± rene; (JS+fegato, OFDVI)
JBTS3	6q23	AHI1	JS±retina (JS+rene)
JBTS4	2q13	NPHP1	JS+ rene
JBTS5	12q21	CEP290	JS+retina+ rene
JBTS6	8q22	TMEM67	JS+ fegato (JS+rene)
JBTS7	16q12	RPGRIP1L	JS+ rene; (JS+ fegato)
JBTS8	3q11	ARL13B	JS
JBTS9	4p15	CC2D2A	JS±retina
JBTS10	Xp22	OFD1	Fenotipo variabile
JBTS11*	2q24	TTC21B	--
JBTS12	15q26	KIF7	JS, (OFDVI)
JBTS13	12q24	TCTN1	JS±retina
JBTS14	2q33	TMEM237	JS+ rene
JBTS15	7q32	CEP41	JS
JBTS16	11q12	TMEM138	Fenotipo variabile
JBTS17	5p13	C5Orf42	JS±retina±caratteristiche OFD
JBTS18	10q24	TCTN3	JS± caratteristiche OFD
JBTS19	16q12	ZNF423	JS+ rene
JBTS20	16q23	TMEM231	JS+retina+ rene
JBTS24	12q24	TCTN2	JS
JBTS21	8q13	CSPP1	JS
JBTS22	2q37	PDE6D	JS+ rene +retina
JBTS	1q42	EXOC8	JS
JBTS28	17q22	MKS1	JS±retina
JBTS27	17p11	B9D1	JS
JBTS34	19q13	B9D2	JS
JBTS25	1p36	CEP104	JS
JBTS29	17p13	TMEM107	JS+retina
JBTS26	16p12	KIAA0556	JS
JBTS33	13q21	PIBF1	JS
JBTS§	11q13	C2CD3	JS+OFD
JBTS§	1p36	NPHP4	JS+ rene
JBTS31	5q23	CEP120	JS
JBTS23	14q23	KIAA0586	JS
JBTS32	10q24	SUFU	JS+SHH-related disorders
JBTS§	2p15	TMEM17	JS+OFD
JBTS§	12q21	POC1B	JS
JBTS§	17p13	KIAA0753	JS+OFD
JBTS30	2q37	ARMC9	JS
	1p13.3	CELSR2	JS
JBTS35	10q24.32	ARL3	JS





2004-2010

2011-2014


2015-2018



JS AND CILIOPATHIES



JS AND CILIOPATHIES



CLINICAL HETEROGENEITY



OVERLAP WITH OTHER CILIOPATHIES




JS GENETIC LANDSCAPE

✓ **447** JS screened probands

✓ **biallelic or XL** variants in 257 (**59%**)



CAUSATIVE VARIANTS
(2nd heterozygous variant missed by sequencing)



Custom **HIGH-RESOLUTION aCGH** focused on JS genes (**CNVs**)



- 37 unrelated JS patients
- exon-disruptive CNVs represent the 2nd HET variant in 6 patients (**16%**)
- Genes: *CEP290*, *NPHP1*, *KIAA0586*, *AH11*, *CPLANE1*



Age and sex prevalence estimate of Joubert syndrome in Italy

Sara Nuovo, MD, Ilaria Bacigalupo, BSc, Monia Ginevrino, BSc, Roberta Battini, MD, PhD, Enrico Bertini, MD, Renato Borgatti, MD, Antonella Casella, PhD, Alessia Micalizzi, PhD, Marta Nardella, PhD, Romina Romaniello, MD, Valentina Serpieri, BSc, Ginevra Zanni, MD, PhD, Enza Maria Valente, MD, PhD, and Nicola Vanacore, MD, PhD, on behalf of the JS Italian Study Group

Neurology® 2020;94:1-5. doi:10.1212/WNL.0000000000008996

Correspondence
Dr. Valente
enzamaria.valente@unipv.it
or Dr. Vanacore
nicola.vanacore@iss.it

- 46 Italian centers
- overall, age- and sex-specific prevalence estimates
- JS in Italy on October 8, 2018 (60,483,973 inhabitants, Istat)
- neuroradiologically confirmed diagnosis of JS

Table 1 Population-based prevalence rate of JS in Italy (per 100,000 population, year 2018)

Age, y	Males			Females			Total	
	Cases, n	Population, n	Rate (95% CI)	Cases, n	Population, n	Rate (95% CI)	Cases, n	Rate (95% CI)
0–4	10	1,249,919	0.80 (0.30–1.30)	10	1,181,740	0.85 (0.32–1.37)	20	0.82 (0.46–1.18)
5–9	32	1,432,161	2.23 (1.46–3.01)	31	1,351,543	2.29 (1.49–3.10)	63	2.26 (1.70–2.82)
10–14	33	1,475,522	2.24 (1.47–3.00)	24	1,389,291	1.73 (1.04–2.42)	57	1.99 (1.47–2.51)
15–19	27	1,504,897	1.79 (1.12–2.47)	21	1,393,182	1.51 (0.86–2.15)	48	1.66 (1.19–2.12)
20–24	20	1,557,238	1.28 (0.72–1.85)	14	1,429,282	0.98 (0.47–1.49)	34	1.14 (0.76–1.52)
25–29	11	1,661,411	0.66 (0.27–1.05)	16	1,587,513	1.01 (0.51–1.50)	27	0.83 (0.52–1.14)
30–34	9	1,712,078	0.53 (0.18–0.87)	9	1,682,623	0.53 (0.19–0.88)	18	0.53 (0.29–0.78)
35–39	5	1,911,532	0.26 (0.03–0.49)	3	1,901,851	0.16 (0.00–0.34)	8	0.21 (0.06–0.36)
>40	9	16,922,849	0.05 (0.02–0.09)	0	19,139,341	0.00 (0.00–0.00)	9	0.02 (0.01–0.04)
Total	156	29,427,607	0.53 (0.45–0.61)	128	31,056,366	0.41 (0.34–0.48)	284	0.47 (0.41–0.52)

Abbreviations: CI = confidence interval; JS = Joubert syndrome.

PAEDIATRIC AGE: **1.70 per 100,000**

Nuovo S et al., 2020

Impaired urinary concentration ability is a sensitive predictor of renal disease progression in Joubert syndrome

Sara Nuovo^{1,2}, Laura Fuiano³, Alessia Micalizzi¹, Roberta Battini^{4,5}, Enrico Bertini⁶, Renato Borgatti⁷, Gianluca Caridi⁸, Stefano D'Arrigo⁹, Elisa Fazzi^{10,11}, Rita Fischetto¹², Gian Marco Ghiggeri⁸, Lucio Giordano¹⁰, Vincenzo Leuzzi¹³, Romina Romaniello⁷, Sabrina Signorini¹⁴, Gilda Stringini³, Ginevra Zanni⁶, Marta Romani¹⁵, Enza Maria Valente^{1,16} and Francesco Emma³


93 patients (76 families) JS

RENAL

- serum/urine electrolytes
- polyuria yes/no
- kidney US
- basal urine osmolality < 800 mOsm/Kg H₂O
- DDAVP test (MINIRIN)

FOLLOW-UP (60 subjects)

- initial normal eGFR
- DURATION (median): 9 [1-14] years



Dempsey JC S et al., 2017

25-30 % of JS patients


NEPHRONOPHTHISIS

- progressive tubular atrophy, interstitial fibrosis
- small corticomedullary cysts
- progression in CKD

CYSTIC DYSPLASTIC KIDNEYS



asymptomatic for years, lack of
BIOMARKER

RENAL FUNCTION: FOLLOW-UP



**CHRONIC KIDNEY DISEASE
IN JS PATIENTS: 29%**

**CANDIDATE BIOMARKER
(URINE OSMOLALITY) FOR
EARLY RECOGNITION OF
RENAL DISEASE**



DL50: probability of adverse renal outcome >50%

DL75: probability of adverse renal outcome >75%






JS-WES APPROACH



macrocephaly/macrosomy/hypertelorism/polydactyly/
frontal bossing/depressed nasal bridge/ PMD/ID




REPRESSOR OF SHH SIGNALING

Conditional KO: polydactyly, cerebellar hypoplasia



mild molar tooth ± polymicrogyria

WES *SUFU* p.Ile406Thr; p.His176Arg



De Mori et al., 2017



JS-WES APPROACH



ARTICLE

Hypomorphic Recessive Variants in **SUFU** Impair the Sonic Hedgehog Pathway and Cause Joubert Syndrome with Cranio-facial and Skeletal Defects




Roberta De Mori,^{1,2,20} Marta Romani,^{3,20} Stefano D'Arrigo,⁴ Maha S. Zaki,⁵ Elisa Loreface,¹ Silvia Tardivo,¹ Tommaso Biagini,⁶ Valentina Stanley,⁷ Damir Musaev,⁷ Joel Fluss,⁸ Alessia Micalizzi,^{1,2} Sara Nuovo,^{1,9} Barbara Illi,¹⁰ Luisa Chiapparini,¹¹ Lucia Di Marcotullio,¹² Mahmoud Y. Issa,⁵ Danila Anello,¹ Antonella Casella,¹ Monia Ginevrino,^{1,13} Autumn Sa'na Leggins,⁷ Susanne Roosing,¹⁴ Romina Alfonsi,¹² Jessica Rosati,¹⁵ Rachel Schot,¹⁶ Grazia Maria Simonetta Mancini,¹⁶ Enrico Bertini,¹⁷ William B. Dobyns,^{18,19} Tommaso Mazza,⁶ Joseph G. Gleeson,⁷ and Enza Maria Valente^{1,13,*}

REPRESSOR OF SHH SIGNALING

Conditional KO: polydactyly, cerebellar hypoplasia





WES *SUFU* p.Ile406Thr; p.His176Arg





PONTOCEREBELLAR HYPOPLASIA

13 SUBTYPES, over 21 GENES

- ✓ 63 screened probands
- ✓ biallelic or XL variants in 46 (73%)



CASK PCH males → 4/25 (16%)






mosaic LoF, severe miss → hemiz LoF

- | | |
|---|--|
| <ul style="list-style-type: none"> • microcephaly • PCH • ID • variable seizures • deafness • butterfly/dragonfly | <ul style="list-style-type: none"> • often lethal • PCH • psychomotor delay • microcephaly • cortical atrophy • seizures |
|---|--|



CLUSTER ANALYSIS



TUB-CEREBELLUM

Eur Radiol
DOI 10.1007/s00330-017-4945-2



NEURO

Tubulin-related cerebellar dysplasia: definition of a distinct pattern of cerebellar malformation


Romina Romaniello¹ · Filippo Arrigoni² · Elena Panzeri³ · Andrea Poretti^{4,5} · Alessia Micalizzi^{6,7} · Andrea Citterio³ · Maria Francesca Bedeschi⁸ · Angela Berardinelli⁹ · Margherita Cusmai¹⁰ · Stefano D'Arrigo¹¹ · Alessandro Ferraris¹² · Annette Hackenberg¹³ · Alma Kuechler¹⁴ · Margherita Mancardi¹⁵ · Sara Nuovo^{6,16} · Barbara Oehl-Jaschkowitz¹⁷ · Andrea Rossi¹⁸ · Sabrina Signorini⁹ · Frank Tüttelmann¹⁹ · Dagmar Wahl²⁰ · Ute Hehr²¹ · Eugen Boltshauser²² · Maria Teresa Bassi³ · Enza Maria Valente^{6,23} · Renato Borgatti¹

- 28 patients mutated in *TUBA1A*, *TUBB2B* or *TUBB3*
- 24 children (age 5m-11y)
- 4 adults (age 22-25y)
- focus on **CEREBELLUM (MRI)**


CEREBELLAR anomalies in 24/28 (86%)



DYSPLASIA in 19/28 (68%)



TUBA1A



TUBB3

“TUBULIN-RELATED CEREBELLAR DYSPLASIA”

- CORTICAL ± VERMIS DYSPLASIA
- PREVALENT UNILATERAL PATTERN (RIGHT >> LEFT)
- OFTEN IN THE POSTERO-SUPERIOR HEMISPHERIC REGION
- REGULAR ASPECT OF THE CEREBELLAR CORTEX (NO CYSTS, THICKENING OF THE CEREBELLAR FOLIA OR SIGNAL ALTERATIONS)




TUBB2B

TUB-BRAINSTEM

European Radiology
<https://doi.org/10.1007/s00330-018-5610-0>


NEURO 



The spectrum of brainstem malformations associated to mutations of the tubulin genes family: MRI and DTI analysis

Filippo Arrigoni¹ · Romina Romaniello² · Denis Peruzzo¹ · Andrea Poretti³ · Maria Teresa Bassi⁴ · Carlo Pierpaoli⁵ · Enza Maria Valente^{6,7} · Sara Nuovo^{7,8} · Eugen Boltshauser⁹ · Thierry André Gerard Marie Huisman³ · Fabio Triulzi¹⁰ · Renato Borgatti²

- 15 patients mutated in *TUBA1A-TUBB2B-TUBB3*
- median age 1.25y (1m-31y)
- focus on **BRAINSTEM (MRI, DTI)**





ANTERIOR CLEFT (40%)

SHORT/SMALL PONS (67%)

IRREGULAR PONTO-MESENCEPHALIC JUNCTION (33%)

SHORT/ASYMMETRIC MCP_s (47%)

"CROSSED ASYMMETRY" PATTERN





altered organisation of WHITE MATTER TRACTS

Cortico-spinal tract (CST)

Transverse Pontine Fibers (TPF)




- (1) THINNING/ATROPHY OF CST
- (2) ABNORMAL COURSE OF CST
- (3) THINNING/THICKENING OF TPF
- (4) IRREGULAR COURSE OF TPF
- (5) COMBINED

TUB-WES APPROACH




**WES analysis: c. 1013G>A
(p.Cys338Tyr) in TTL**

- commissure agenesis/hypoplasia
- hypodysplastic-counterclockwise rotated cerebellar vermis
- horizontalized SCPs
- enlarged 4th ventricle
- dysplastic brainstem
- dysplastic internal capsule




**DECREASED LEVELS OF TTL mutant protein
and HIGHER DETYROSINATED TUBULIN
EXPRESSION**

TUB-WES APPROACH



BOTH TTL MUTANTS ARE ENZYMATICALLY INACTIVE




INCREASED AXONAL LENGTH

RECESSIVELY INHERITED TUBULINOPATHY-LIKE DISORDER, CAUSED BY BIALLELIC LOSS OF FUNCTION MUTATIONS IN THE *TTL* GENE



NPCA-SPTBN2



SPTBN2 c.11438C>T;
p.Arg480Trp

- 2-YEAR-OLD GIRL
- GENERALIZED HYPOTONIA, GLOBAL DEVELOPMENTAL DELAY, ALTERNATING ESOTROPIA
- CEREBELLAR SYNDROME WITH GAIT ATAXIA AND DYSARTHRIA
- MRI: GLOBAL CEREBELLAR HYPOPLASIA WITH ENLARGED INTERFOLIAL SPACES

Nuovo S et al., 2018

	SCAS					1480W-phenotype"	SCAR14			
Reference	2	2	2	3	4	3, 9, present study	6	1	5	7
Genetic variant	c.1592_1630del p.E532_M544del	c.1886_1900del p.L629_R634 delinsW	c.758T>C p.L253P	c.1415 C>T p.T472M	c.2608_2610del p.E870del	c.11438C>T p.R480W	c.6375-1G>C	c.2864_2868del p.T955Sfs*120	c.1881C>A p.C627X	c.1572C>T p.R414C
Inheritance			het AD			het de novo		hom AR		
Exon	12	14	7	12	14	12	splice site	16	14	2
Domain	3rd SPEC	3rd SPEC	CH	2nd SPEC	6th SPEC	2nd SPEC	PH	6th SPEC	3rd SPEC	1st SPEC
N. of affected	90	6	12	3	5	3	9	3	3	2
Mean age of onset (years)	45	27	33	45	53	congenital		congenital		
Cerebellar syndrome	+	+	+	+	+	+	+	+	+	+
Abnormal ocular movements	-	+	+	-	-	+	-	-	+	+
Hypotonia	-	-	-	-	-	2/3	+	-	1/3	+
Pyramidal signs	4/90	5/6	-	-	1/5	1/3	-	+	-	-
Tremor	-	-	7/12	-	-	1/3	3/9	-	-	-
Focal dystonia	-	1/6	-	-	-	-	-	-	-	-
Facial myokymia	-	4/6	-	-	-	1/3	-	-	-	-
Bulbar dysfunction	2/90	-	-	-	1/5	-	-	-	-	-
DD/ID	-	-	-	-	-	+	+	+	+	+
Behavioral problems	-	-	-	-	-	-	8/8 ^c	-	-	-
Cerebellar atrophy	+	+	+	+	+	+ ^a	+	NA	2/3 ^e	+
Clinical progression	+	+	+	+	+	1/2 ^b	+ ^d	no	no	no

AS-HIP

CORRESPONDENCE




Between SCA5 and SCAR14: delineation of the *SPTBN2* p.R480W-associated phenotype

Sara Nuovo^{1,2} · Alessia Micalizzi¹ · Stefano D'Arrigo³ · Monia Ginevrino^{1,4} · Tommaso Biagini⁵ · Tommaso Mazza⁵ · Enza Maria Valente^{1,4}

Inheritance	het AD					het de novo	hom AR			
	Exon 12	Exon 14	Exon 7	Exon 12	Exon 14		splice site	Exon 16	Exon 14	Exon 2
Domain	3rd SPEC	3rd SPEC	CH	2nd SPEC	6th SPEC	2nd SPEC	PH	6th SPEC	3rd SPEC	1st SPEC
N. of affected	90	6	12	3	5	3	9	3	3	2
Mean age of onset (years)	45	27	33	45	53	congenital		congenital		
Cerebellar syndrome	+	+	+	+	+	+	+	+	+	+
Abnormal ocular movements	-	+	+	-	-	+	-	-	+	+
Hypotonia	-	-	-	-	-	2/3	+	-	1/3	+
Pyramidal signs	4/90	5/6	-	-	1/5	1/3	-	+	-	-
Tremor	-	-	7/12	-	-	1/3	3/9	-	-	-
Focal dystonia	-	1/6	-	-	-	-	-	-	-	-
Facial myokymia	-	4/6	-	-	-	1/3	-	-	-	-
Bulbar dysfunction	2/90	-	-	-	1/5	-	-	-	-	-
DD/ID	-	-	-	-	-	+	+	+	+	+
Behavioral problems	-	-	-	-	-	-	8/8 ^c	-	-	-
Cerebellar atrophy	+	+	+	+	+	+ ^a	+	NA	2/3 ^e	+
Clinical progression	+	+	+	+	+	1/2 ^b	+ ^d	no	no	no

15-HIP

ACKNOWLEDGEMENTS



❖ ASSOCIAZIONE AISJAC

❖ Prof.ssa Enza Maria Valente

- Alessia Micalizzi, Monia Ginevrino, Roberta De Mori, Simona Petrucci, Silvia Tardivo, Antonella Casella, Elisa Loreface, Danila Anello, Romina Cutigni
- Ivan Limongelli (enGenome)

❖ Collaborazioni Internazionali

- Joe Gleeson (San Diego)
- Eugen Boltshauser, (Zurich, Baltimore)
- Tania Attie-Bitach (Paris)
- The International JSRD Study Group

Andrea Poretti, M.D.



Assistant Professor of
Radiology and Radiological
Science

Expertise: Pediatric Imaging,
Pediatric Neurology

Aprile 1977-Marzo 2017



illumina®



The Italian CBCD Project



Ministero della Salute



European Research Council
Scientific Council



Ad Andrea



SANTA LUCIA
NEUROSCIENZE
E RIABILITAZIONE